Echo Street Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Echo Street Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,282	Closed	-$257K	–	452
2023 Q1	$257K	Buy	+1,282	New	+$269K	﹤0.01%	411
2022 Q2	–	Sell	-2,101	Closed	-$343K	–	554
2022 Q1	$343K	Sell	2,101 -1,830	-47%	-$279K	﹤0.01%	484
2021 Q4	$667K	Buy	3,931 +2,111	+116%	+$392K	﹤0.01%	347
2021 Q3	$344K	Buy	+1,820	New	+$341K	﹤0.01%	498
2021 Q2	–	Sell	-3,019	Closed	-$426K	–	582
2021 Q1	$426K	Buy	3,019 +1,033	+52%	+$155K	﹤0.01%	338
2020 Q4	$258K	Buy	+1,986	New	+$265K	﹤0.01%	335

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Echo Street Capital Management's ALNY Position: Q2 2023 in Review

Echo Street Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 1,282 shares — an estimated $257K sold.

Echo Street Capital Management first reported a position in ALNY in Q4 2020 and held it in 6 quarters. The position peaked at $667K in Q4 2021. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

Echo Street Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Echo Street Capital Management sold 1,282 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $257K.
Echo Street Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Echo Street Capital Management's Alnylam Pharmaceuticals position peaked at $667K in Q4 2021.
476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on Echo Street Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.